Leap Therapeutics Inc (NASDAQ:LPTX)
| 1.97 Delayed Data As of Sep 18 |  +0.06 / +3.14%Today’s Change | 0.57 Today|||52-Week Range 3.18 | +75.89% Year-to-Date |
Latest LPTX News | Press Releases
| Leap Therapeutics files for $150M mixed shelf Sep 14 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 1.91 |
| Today’s open | 1.92 |
| Day’s range | 1.92 - 2.04 |
| Volume | 31,893 |
| Average volume (3 months) | 749,741 |
| Market cap | $111.9M |
Data as of 3:59pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | +9.96% |
| Earnings growth (this year) | +47.48% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CSBRChampions Oncology I... | +0.48 | +5.57% |
| PLXProtalix Biotherapeu... | +0.16 | +4.42% |
| VCNXVaccinex Inc | -0.25 | -4.22% |
| SRRASierra Oncology Inc | -0.52 | -4.35% |
Data as of 3:58pm ET, 09/18/2020
Financials
| Next reporting date | November 11, 2020 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$32.9M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
